Musa Yilmaz, MD, of The University of Texas MD Anderson Cancer Center, discusses study results suggesting that quizartinib with decitabine and venetoclax is active in patients with FLT3-ITD–mutated acute myeloid leukemia and that RAS/MAPK mutations continue to drive primary and secondary resistance (Abstract 370).
Daniel A. Ermann, MD, of the Huntsman Cancer Institute, University of Utah, discusses results from the largest retrospective study on outcomes utilizing radiotherapy in early-stage diffuse large B-cell lymphoma. Adding radiation to front-line multiagent chemotherapy was associated with a survival benefit for all patients with early-stage disease. An overall survival benefit was seen with the addition of radiation to front-line multiagent chemotherapy for patients with nodal involvement and those with specific extranodal involvement in the testes, thyroid, skin and soft tissue, and head and neck (Abstract 49).
Matthew S. Davids, MD, of Dana-Farber Cancer Institute, discusses phase II results from a multicenter study that showed the efficacy of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in younger, fit patients with chronic lymphocytic leukemia who desire the possibility of a functional cure with time-limited therapy (Abstract 640).
Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, discusses disease-free survival results from the measurable residual disease cohort of the phase II CAPTIVATE trial. This multicenter trial focuses on first-line ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia (Abstract 68).
Sangeetha Venugopal, MD, of The University of Texas MD Anderson Cancer Center, discusses a retrospective analysis of 562 patients with treated secondary acute myeloid leukemia and prior exposure to hypomethylating agents (HMAs). The results showed that an HMA plus venetoclax yielded significantly higher overall response rates and improved overall survival compared with intensive chemotherapy or low-intensity chemotherapy, particularly in patients 60 years or older who had a karyotype without adverse risk (Abstract 794).
Romanos Sklavenitis-Pistofidis, MD, of Dana-Farber Cancer Institute, discusses study findings on a next generation of clinical assays to assess both tumor biology and immune state, as well as common clinical biomarkers in the marrow or blood. These biomarkers may accurately predict which patients with smoldering multiple myeloma might benefit from early treatment, monitor response to immunotherapy, and improve patient outcomes (Abstract 330).
